10 Top Performing European Stocks Heading into 2025

5) Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

% Increase on a YTD Basis: ~23%

Average Upside Potential: ~53.1%

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a biopharmaceutical company, which focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases having unmet medical needs. The company is based out of London, the United Kingdom.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s focus on disease awareness and expanding prescriber adoption demonstrated promising Q3 2024 results. This is evidenced by the fact that more than 2,550 prescribers (since its launch in April 2021) have written ARCALYST prescriptions for recurrent pericarditis. As of the end of Q3 2024, the average total duration of ARCALYST therapy in recurrent pericarditis rose to ~27 months. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s clinical pipeline, which includes the ongoing trials for abiprubart in Sjögren’s disease, remains the priority.

Notably, consistent execution throughout the commercial organization, which includes strategic investments in brand and disease awareness, continued to fuel ARCALYST’s growth among new and repeat prescribers.

For 2024, Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) expects ARCALYST net sales to increase to between $410 million and $420 million. Within the pipeline, the company has been enrolling and dosing patients in the Phase 2b clinical trial of abiprubart in Sjögren’s disease. It expects to remain cash flow positive on an annual basis while continuing to invest throughout its business, including commercialization and pipeline advancement.

As per industry experts, disease awareness campaigns and commercial strategies have been increasing prescriber adoption. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) expects continued growth in ARCALYST sales and prescriber numbers, with a strong emphasis on increasing disease awareness and diagnosis for recurrent pericarditis. The company continues to focus on making investments, targeting to bring new treatments to the market for debilitating diseases.

Analysts at Evercore ISI increased their target price on the shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) from $30.00 to $35.00, giving an “Outperform” rating on 30th October.